Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) EBT Margin (2021 - 2025)

Tarsus Pharmaceuticals has reported EBT Margin over the past 5 years, most recently at 4.11% for Q4 2025.

  • Quarterly results put EBT Margin at 4.11% for Q4 2025, up 3065.0% from a year ago — trailing twelve months through Dec 2025 was 14.21% (up 4777.0% YoY), and the annual figure for FY2025 was 14.26%, up 4890.0%.
  • EBT Margin for Q4 2025 was 4.11% at Tarsus Pharmaceuticals, up from 10.69% in the prior quarter.
  • Over the last five years, EBT Margin for TARS hit a ceiling of 33.11% in Q2 2021 and a floor of 4271.01% in Q4 2021.
  • Median EBT Margin over the past 5 years was 62.73% (2024), compared with a mean of 723.33%.
  • Peak annual rise in EBT Margin hit 413475bps in 2022, while the deepest fall reached -371241bps in 2022.
  • Tarsus Pharmaceuticals' EBT Margin stood at 4271.01% in 2021, then skyrocketed by 97bps to 136.26% in 2022, then crashed by -138bps to 324.72% in 2023, then surged by 89bps to 34.76% in 2024, then skyrocketed by 88bps to 4.11% in 2025.
  • The last three reported values for EBT Margin were 4.11% (Q4 2025), 10.69% (Q3 2025), and 19.67% (Q2 2025) per Business Quant data.